Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis
Immunology · 2024
DOI: 10.1111/imm.13855 ↗At a glance
Übersichtsarbeit in Immunology, 2024. Written by Fatmawati Lambuk and 8 co-authors. Institution: Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia. Major MEDLINE topics: Arthritis, Rheumatoid, Receptors, Tumor Necrosis Factor, Type II, Nanomedicine. Cited 2 times so far (Crossref); 91 references. Funded by: Ministry of Higher Education, Malaysia; Fundamental Research Grant Scheme.
Abstract (original language)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium and progressive joint destruction which significantly affects both quality of life and socioeconomic status. Admittedly, various treatments are available, but they are usually accompanied by various side effects, from mild to severe, and potentially with adverse events. Tumour necrosis factor‐alpha (TNF‐α) plays a crucial role in the pathophysiology of RA. It promotes inflammatory, apoptosis and necroptosis via TNF receptor‐1 (TNFR1) but elicit anti‐inflammatory effects via TNFR2. Herein, targeting TNFR2 has gained attention in RA studies. Understanding the role of nanomedicine in modulating TNFR2 signalling may be the instrument in development of RA therapies. Nanotechnology has made a significant progress in treating various conditions of diseases since its inception. Due to this, nanomedicine has emerged as a promising therapeutics approach for RA. Recent studies have demonstrated the potential of nanomedicine in RA theranostics, combining therapy and diagnostics for improved treatment outcomes. Owing to the challenges and advancements in the field of nanotechnology, nanoparticles are seen as an applicable candidate in the treatment of RA. In this review, we provide an overview of the role of nanomedicine in targeting TNFR2 for the treatment of RA and highlight the limitations of current therapies as well as the potential of nanocarriers with controlled drug release and active targeting abilities.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
- Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.
- Department of Biology, Faculty of Education, Omdurman Islamic University, Omdurman, Sudan.
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
ORCID profiles: Fatmawati Lambuk, Ali Mussa
Funding
- Ministry of Higher Education, Malaysia; Fundamental Research Grant Scheme
Cite
APA
Lambuk, F., Nordin, N. A., Mussa, A., Lambuk, L., Ahmad, S., Hassan, R., Kadir, R., Mohamud, R., & Yahya, N. K. (2024). Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis. Immunology. https://doi.org/10.1111/imm.13855
Vancouver
Lambuk F, Nordin NA, Mussa A, Lambuk L, Ahmad S, Hassan R, et al. Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis. Immunology. 2024. doi:10.1111/imm.13855
BibTeX
@article{Lambuk2024,
author = {Lambuk, Fatmawati and Nordin, Nor Asyikin and Mussa, Ali and Lambuk, Lidawani and Ahmad, Suhana and Hassan, Rosline and Kadir, Ramlah and Mohamud, Rohimah and Yahya, Nurul Khaiza},
title = {Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13855}
}
EUVIMED